TFF Pharmaceuticals enters ATM equity offering agreement with H.C. Wainwright

TFF Pharmaceuticals, Inc.

Agreement allows sale of common stock at Company's discretion under effective S-3 registration statement.
Agent commission set at 3% of gross proceeds; Company reimburses up to $50,000 in expenses.
Sales may be made through at-the-market offerings, including negotiated and block transactions.
No minimum or maximum offering amount specified; proceeds for general corporate purposes.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

TFF Pharmaceuticals, Inc. entered into At The Market Offering Agreement with H.C. Wainwright & Co., LLC (effective 2024-05-17).

Action: entry
Agreement: atm program
Counterparty: H.C. Wainwright & Co., LLC
Effective: 2024-05-17

Exact text from the filing

On May 17, 2024, TFF Pharmaceuticals, Inc. (the “Company”) entered into an At The Market Offering Agreement (the “Agreement”) with H.C. Wainwright & Co., LLC (“Agent”) under which the Company may offer and sell, from time to time at its sole discretion, shares of its $0.001 par value common stock (“Common Stock”), through the Agent as its sales agent.

View on SEC.gov

290 material agreements filed in the last 30 days. Browse all material agreements →

Source: SEC EDGAR

accession 0001213900-24-044746

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.